Skip to main content

Free Content Immunologic Effects of Intranasal Corticosteroids

Download Article:
(PDF 854.4443359375 kb)


Intranasally administered corticosteroids have a wide margin of safety and are the mainstay of treatment for patients with moderate to severe allergic rhinitis, nonallergic rhinitis, and nasal polyposis. Long term use in recommended dosages has not caused nasal mucosal atrophy or hypothalamic-pituitary-adrenal (HPA) suppression. In practice, although fluticasone propionate and flunisolide appear to be twice as potent as beclomethasone dipropionate, there is little, if any, difference in therapeutic effectiveness (maximum achievable effect) among any of the currently available preparations. Intranasally administered corticosteroids can 1) inhibit the early and late (3–11 hour) responses following experimental allergen challenge, 2) reduce the number of eosinophils and basophils in nasal lavage samples, and 3) decrease the number of activated (CD4+CD25+) lymphocytes and presence of bioactive mediators. The number of interleukin 4 (IL-4) reactive cells is decreased in the nasal submucosa, which is of importance in that IL-4 participates in IgE synthesis, T cell activation, and vascular cell adhesion molecule (VCAM) upregulation. The beneficial immunologic actions and nasal protective properties of intranasal corticosteroids have resulted in widespread use and reduction in patient rhinitic symptoms. Nevertheless, intranasal corticosteroids are not a substitute for environmental control, cessation of smoking, or determination whether allergen immunotherapy is indicated.

Document Type: Editorial


Publication date: 1996-05-01

More about this publication?
  • Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.

    The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.

    Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.

    Articles marked "F" offer free full text for personal noncommercial use only.

    The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Information for Advertisers
  • Reprint Requests
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more